Nexome Scan & Nexome Discover - NGS Analytics Solutions
High throughput, next-generation sequencing technologies allow for millions to even billions of DNA strands to be sequenced in parallel. There is an abundance of use cases for NGS technologies in scientific research, including personalized medicine, cancer research, drug discovery, biomarker discovery, and agricultural & animal sciences.
We are developing a cloud-based NGS data analytics and reporting system, Nexome Scan and Nexome Discover respectively. When fully implemented, Nexome Scan will provide genomic data storage and on-demand diagnostic and prognostic report generation through Nexome Discover to medical centers, hospitals, physician offices, and other institutions in need of precise clinical reporting of sequencing diagnostic information.
This method of genomic data analysis, supported by a cloud-based backbone, will drastically shift the current person-to-person service model to an online service model that offers unique genetic diagnostics through a secure and trusted reporting system. Our solution utilizes advanced bioinformatics and statistical analysis methodologies, and integrates with large-scale public and proprietary genomic resources to create a next-generation diagnostic platform that allows health care institutions to capture opportunities in the growing personalized medicine field.
We are developing a cloud-based NGS data analytics and reporting system, Nexome Scan and Nexome Discover respectively. When fully implemented, Nexome Scan will provide genomic data storage and on-demand diagnostic and prognostic report generation through Nexome Discover to medical centers, hospitals, physician offices, and other institutions in need of precise clinical reporting of sequencing diagnostic information.
This method of genomic data analysis, supported by a cloud-based backbone, will drastically shift the current person-to-person service model to an online service model that offers unique genetic diagnostics through a secure and trusted reporting system. Our solution utilizes advanced bioinformatics and statistical analysis methodologies, and integrates with large-scale public and proprietary genomic resources to create a next-generation diagnostic platform that allows health care institutions to capture opportunities in the growing personalized medicine field.
NexoSeq - Proprietary and Unique Cancer Panels
Next-generation sequencing (NGS) technologies are capable of discovering gene-specific mutations that are potentially tumorigenic. Nexome currently has 2 different panels that utilize NGS technologies for cancer diagnosis. Our panels are expertly designed using published datasets and a vast in-house store of cancer profiling results from comprehensive algorithms developed by world-renowned cancer genomics experts and computational biologists. Nexome’s robust development process ensures that our panels accurately identify all alterations in a patient’s tumor sample, thus enabling the clinician and patient to explore all available treatment options.
NexoSeq Oncology
A comprehensive pan-cancer panel specifically designed for mutation analysis
NexoSeq Oncology targets approximately 200 genes that are linked to major mutations from different cancer types. Developed using data from large-scale cancer genome studies such as The Cancer Genome Atlas (TCGA), which covers more than 6000 tumors, this comprehensive panel offers insight into the underlying mechanisms of cancer initiation and progression. NexoSeq Oncology covers gene functions in transcription, cell cycle, genome stability, histone modification, etc., as well as genes associated with cancer predisposition, such as VHL, KRAS, PTEN, and TP53.
A comprehensive pan-cancer panel specifically designed for mutation analysis
NexoSeq Oncology targets approximately 200 genes that are linked to major mutations from different cancer types. Developed using data from large-scale cancer genome studies such as The Cancer Genome Atlas (TCGA), which covers more than 6000 tumors, this comprehensive panel offers insight into the underlying mechanisms of cancer initiation and progression. NexoSeq Oncology covers gene functions in transcription, cell cycle, genome stability, histone modification, etc., as well as genes associated with cancer predisposition, such as VHL, KRAS, PTEN, and TP53.
NexoSeq Breast Cancer
A fine-tuned panel for breast cancer diagnosis
While hereditary breast cancers tend to occur earlier than sporadic cancers, two genes — BRCA1 and BRCA2 — appear to be responsible for around half of all instances of hereditary breast cancer. Additional genes have been added to the panel based on their links to breast cancers as determined by various large breast cancer profiling and genome-wide association studies, or by their occurrence rates and DNA amplification status. Approximately 50 genes are included in this targeted panel to enable deeper coverage or multiplexing of tumor samples.
A fine-tuned panel for breast cancer diagnosis
While hereditary breast cancers tend to occur earlier than sporadic cancers, two genes — BRCA1 and BRCA2 — appear to be responsible for around half of all instances of hereditary breast cancer. Additional genes have been added to the panel based on their links to breast cancers as determined by various large breast cancer profiling and genome-wide association studies, or by their occurrence rates and DNA amplification status. Approximately 50 genes are included in this targeted panel to enable deeper coverage or multiplexing of tumor samples.
NexoSeq Liver Cancer
A comprehensive coverage for liver cancer diagnosis
Hepatocellular carcinoma (HCC) is the most deadly liver cancer with a poor outcome. Multiple studies have indicated that signaling pathways such as WNT, TGF beta, JAK1 and others are commonly dysregulated in HCC. Hepatitis B or C virus (HBV and HCV) infection causes the majority of HCC cases worldwide. Genetic alterations HCC have been identified previously, including mutations in TP53 and beta-catenin, amplifications of MYC and FGF19, and mutation in TERT promoter region. NexoSeq liver cancer panel provides a comprehensive coverage of genes mutated in liver cancer to enable diagnosis, understanding of gene dysregulation in major pathways.
A comprehensive coverage for liver cancer diagnosis
Hepatocellular carcinoma (HCC) is the most deadly liver cancer with a poor outcome. Multiple studies have indicated that signaling pathways such as WNT, TGF beta, JAK1 and others are commonly dysregulated in HCC. Hepatitis B or C virus (HBV and HCV) infection causes the majority of HCC cases worldwide. Genetic alterations HCC have been identified previously, including mutations in TP53 and beta-catenin, amplifications of MYC and FGF19, and mutation in TERT promoter region. NexoSeq liver cancer panel provides a comprehensive coverage of genes mutated in liver cancer to enable diagnosis, understanding of gene dysregulation in major pathways.
NexoSeq Prostate Cancer
A treatment and management guideline for clinical diagnosis
The Prostate Cancer Panel uses next-generation sequencing and insertion/deletion analysis to analyze a focused panel of 40 genes associated with prostate cancer. Most frequent mutated genes in prostate, such as TP53, TMPRSS2, PTEN, and AR, as well as genes associated to hereditary prostate cancer (about 5-10%), such as BRCA1, BRCA2 and CHEK are included. The test may be used to confirm a clinical diagnosis and/or to guide decisions for treatment and management.
A treatment and management guideline for clinical diagnosis
The Prostate Cancer Panel uses next-generation sequencing and insertion/deletion analysis to analyze a focused panel of 40 genes associated with prostate cancer. Most frequent mutated genes in prostate, such as TP53, TMPRSS2, PTEN, and AR, as well as genes associated to hereditary prostate cancer (about 5-10%), such as BRCA1, BRCA2 and CHEK are included. The test may be used to confirm a clinical diagnosis and/or to guide decisions for treatment and management.
NexoSeq Lung Cancer
A targeted panel for lung cancer diagnosis
Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancers and the most common lung cancer in US is predominantly adenocarcinomas, and the less common squamous cell carcinomas. Mutation information may be used to determine the eligibility for tyrosine kinase inhibitor therapy. For example, The EGFR mutation is present in >10% of lung adenocarcinomas, which predicts response to drugs such as erlotinib. Identifying mutations in oncogenes, such as EGFR, KRAS, and ALK, associated with NSCLC can distinguish patients who are more likely to benefit from a targeted therapy.
A targeted panel for lung cancer diagnosis
Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancers and the most common lung cancer in US is predominantly adenocarcinomas, and the less common squamous cell carcinomas. Mutation information may be used to determine the eligibility for tyrosine kinase inhibitor therapy. For example, The EGFR mutation is present in >10% of lung adenocarcinomas, which predicts response to drugs such as erlotinib. Identifying mutations in oncogenes, such as EGFR, KRAS, and ALK, associated with NSCLC can distinguish patients who are more likely to benefit from a targeted therapy.